EXOZYMES INC.
Close on Oct 19, 2026
- Market cap
- $34.64M
- P/E (TTM)
- –
- Dividend yield
- –
About Exozymes
Biological Products, (No Diagnostic Substances), SIC 2836
eXoZymes Inc. is a biomanufacturing platform company that develops cell-free biosolutions to produce chemicals and small-molecule active ingredients. The company leverages artificial intelligence and bioengineering to design stabilized enzyme catalysts, termed exozymes, which operate outside living cells within bioreactors to convert feedstocks into valuable compounds. Its primary commercial focus targets low-volume, high-value natural products and derivatives for the nutraceutical sector that possess potential application as active pharmaceutical ingredients. Additionally, the company develops specialized programs including an exozyme pathway for isobutanol production to support sustainable aviation fuels and industrial chemical applications. Its customers and collaborative partners comprise commercial entities in the nutraceutical and pharmaceutical industries, as well as government agencies supporting applied research.
The company operates its research and development activities from a state-of-the-art laboratory facility. Headquartered in Monrovia, California, eXoZymes conducts its administrative and development functions within the United States.
Summary of the business section of Exozymes's latest annual report, written by StockData.
Company profile
Company
- Legal name
- EXOZYMES INC.
- Headquarters
- Monrovia, CA
- Address
- 750 Royal Oaks Dr 91016
- Phone
- (626) 415-1488
- Employees
- 32, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- RBSM LLP, Las Vegas, Nevada
Stock & identifiers
- Ticker
- EXOZ
- Exchange
- Nasdaq
- IPO date
- Nov 12, 2024
- Shares outstanding
- 9M, Aug 13, 2026
- Public float
- $38.42M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 2010788
- CUSIP
- 461874109
- ISIN
- US4618741098
- EIN
- 83-4550057
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Mohammad Hayat | President & Chairman of Board, Director | 155,818 |
| Fouad Nawaz | Vice President- Finance | 9,488 |
| Michael Heltzen | Chief Executive Officer | 14,708 |
| Tyler Paz Korman | Chief Scientific Officer | 762,837 |
| Damien Alan Perriman | Chief Commercial Officer | 28,499 |
| Paul Hideo Opgenorth | Vice President, Development | 645,149 |
| Edgardo Javier Rayo | Director | 77,909 |
| Lon E. Bell | Director | – |
| Christopher A. Marlett | Director | 3,808,476 |
| James Joseph Lalonde | Director | – |
| James Ulrich Bowie | Director | 577,910 |
| Anthony Digiandomenico | Director | 3,808,476 |
Employees
Headcount reported in annual reports
“of December 31, 2025, eXoZymes boasts a dedicated team of approximately 32 full-time employees or equivalents.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jan 21, 2025 | Name change | Name changed from Invizyne Technologies Inc to EXOZYMES INC. |
| Nov 12, 2024 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 1, 2024 | Listing | Registration of securities on an exchange (Form 8-A) |